Literature DB >> 166929

Failure of attenuated temperature-sensitive influenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus.

B R Murphy, D D Richman, E G Chalhub, C P Uhlendorf, S Baron, R M Chanock.   

Abstract

The present investigation was undertaken to determine if a candidate live vaccine virus, influenza A/Hong Kong/68-ts-1 [E] (H3N2), induced heterologous interference against an interferon-sensitive, wild-type, parainfluenza type 1 challenge virus. The parainfluenza virus was administered 7 days after Hong Kong/68-ts-1 [E] virus infection. The clinical response, daily quantitative virus shedding, interferon production, and serum and nasal wash antibody responses were determined in an experimental group (influenza A virus followed by parainfluenza virus) and 10 volunteers in a control group (parainfluenza virus only). The volunteers were selected on the basis of susceptibility to the two viruses, i.e. serum hemagglutination-inhibition antibody titer of is less than or greater to 1:8 for influenza virus and low nasal wash antibody titer (is less than or greater to 1:8) for parainfluenza virus. Despite a 100% infection rate in the Hong Kong/68-ts-1 [E] vaccinees, no heterologous interference was induced against the parainfluenza type 1 virus challenge.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 166929      PMCID: PMC415245          DOI: 10.1128/iai.12.1.62-68.1975

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  Improved assays for a variety of interferons. 1.

Authors:  H K Oie; C E Buckler; C P Uhlendorf; D A Hill; S Baron
Journal:  Proc Soc Exp Biol Med       Date:  1972-09

2.  Epidemiology of acute lower respiratory disease in children.

Authors:  P Glezen; F W Denny
Journal:  N Engl J Med       Date:  1973-03-08       Impact factor: 91.245

3.  Interferon and resistance to upper respiratory virus illness.

Authors:  T R Cate; R G Douglas; R B Couch
Journal:  Proc Soc Exp Biol Med       Date:  1969-06

Review 4.  Interference in human viral infections: present status and prospects for the future.

Authors:  E F Wheelock; R P Larke; N L Caroline
Journal:  Prog Med Virol       Date:  1968

5.  Respiratory virus vaccines. 8. Field evaluation of trivalent parainfluenza virus vaccine among preschool children in families, 1967-1968.

Authors:  P P Vella; R E Weibel; A F Woodhour; C C Mascoli; M B Leagus; O L Ittensohn; J Stokes; M R Hilleman
Journal:  Am Rev Respir Dis       Date:  1969-04

6.  Role of interferon during viremia. II. Protective action of circulating interferon.

Authors:  S Baron; C E Buckler; R M Friedman; R V McCloskey
Journal:  J Immunol       Date:  1966-01       Impact factor: 5.422

7.  Protective effect of antibody to parainfluenza type 1 virus.

Authors:  C B Smith; R H Purcell; J A Bellanti; R M Chanock
Journal:  N Engl J Med       Date:  1966-11-24       Impact factor: 91.245

8.  Homologous and heterologous resistance to rhinovirus common cold.

Authors:  W F Fleet; R B Couch; T R Cate; V Knight
Journal:  Am J Epidemiol       Date:  1965-09       Impact factor: 4.897

9.  Sensitivity of common respiratory viruses to an interferon inducer in human cells.

Authors:  D A Hill; S Baron; R M Chanock
Journal:  Lancet       Date:  1969-07-26       Impact factor: 79.321

10.  The effect of prior inoculation with an enterovirus (LEV 4) on rhinovirus infection of volunteers.

Authors:  T H Matthews; S E Reed; D A Tyrrell
Journal:  Arch Gesamte Virusforsch       Date:  1974
View more
  19 in total

Review 1.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

2.  Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice.

Authors:  Makiko Watanabe; Vasiliy P Mishin; Scott A Brown; Charles J Russell; Kelli Boyd; Y Sudhakara Babu; Garry Taylor; Xiaoping Xiong; Xiaowei Yan; Allen Portner; Irina V Alymova
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

3.  Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.

Authors:  T Tao; A P Durbin; S S Whitehead; F Davoodi; P L Collins; B R Murphy
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

4.  Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys.

Authors:  Anne Schaap-Nutt; Margaret A Scull; Alexander C Schmidt; Brian R Murphy; Raymond J Pickles
Journal:  Vaccine       Date:  2010-02-20       Impact factor: 3.641

5.  Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium.

Authors:  Emmalene J Bartlett; Margaret Hennessey; Mario H Skiadopoulos; Alexander C Schmidt; Peter L Collins; Brian R Murphy; Raymond J Pickles
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

6.  Three strains of influenza A virus (H3N2): interferon sensitivity in vitro and interferon production in volunteers.

Authors:  D D Richman; B R Murphy; S Baron; C Uhlendorf
Journal:  J Clin Microbiol       Date:  1976-03       Impact factor: 5.948

7.  Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates.

Authors:  Emmalene J Bartlett; Ann-Marie Cruz; Janice Esker; Adam Castaño; Henrick Schomacker; Sonja R Surman; Margaret Hennessey; Jim Boonyaratanakornkit; Raymond J Pickles; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

8.  A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates.

Authors:  Emmalene J Bartlett; Ann-Marie Cruz; Jim Boonyaratanakornkit; Janice Esker; Adam Castaño; Mario H Skiadopoulos; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Journal:  Vaccine       Date:  2009-10-24       Impact factor: 3.641

9.  Use of the enzyme-linked immunosorbent assay to detect serum antibody responses of volunteers who received attenuated influenza A virus vaccines.

Authors:  B R Murphy; E L Tierney; B A Barbour; R H Yolken; D W Alling; H P Holley; R E Mayner; R M Chanock
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

10.  Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.

Authors:  Jason T Newman; Jeffrey M Riggs; Sonja R Surman; Josephine M McAuliffe; Teresa A Mulaikal; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.